Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Yan, Xiaoxiang ^a,b   Sano, Motoaki ^b   Lu, Lin ^a   Wang, Wei ^a   Zhang, Qi ^a   Zhang, Ruiyan ^a   Wang, Lingjie ^a   Chen, Qiujing ^a   Fukuda, Keiichi ^b   Shen, Weifeng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OSTEOPONTIN; THROMBIN; BIOLOGICAL MARKER; SPP1 PROTEIN, HUMAN;

ADULT; ANGIOGRAPHY; ARTERY DIAMETER; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY FAILURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAMETER; RISK ASSESSMENT; AGED; ANGIOCARDIOGRAPHY; BLOOD; CASE CONTROL STUDY; CHINA; HOSPITALIZATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RADIOGRAPHY; RISK FACTOR; STATISTICAL MODEL;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHINA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; OSTEOPONTIN; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBIN;

EID: 77958566739     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-70     Document Type: Article

References (37)

1. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009, 53:S35-42. 10.1016/j.jacc.2008.09.055, 2663393, 19179216.
2. Al-Maskari F, El-Sadig M, Norman JN. The prevalence of macrovascular complications among diabetic patients in the United Arab Emirates. Cardiovasc Diabetol 2007, 6:24. 10.1186/1475-2840-6-24, 2093928, 17880686.
3. Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, Chen QJ, Shen WF. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 2009, 205:544-548. 10.1016/j.atherosclerosis.2008.12.016, 19150066.
4. Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 2009, 8:61. 10.1186/1475-2840-8-61, 2789050, 19930630.
5. Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, Zhang JS, Hu J, Yang ZK, Ding FH, Chen QJ, Lou S, Shen J, Fang DH, Shen WF. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006, 5:27. 10.1186/1475-2840-5-27, 1764721, 17178005.
6. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007, 27:2302-2309. 10.1161/ATVBAHA.107.144824, 17717292.
7. Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, Kobayashi H, Shimizu M, Katada Y, Wakitani S, Murata N, Nomura S, Matsuno H, Katayama R, Kon S, Inobe M, Uede T, Kawase I, Saeki Y. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 2002, 29:2061-2067.
8. Okamoto H. Osteopontin and cardiovascular system. Mol Cell Biochem 2007, 300:1-7. 10.1007/s11010-006-9368-3, 17136480.
9. Takemoto M, Yokote K, Nishimura M, Shigematsu T, Hasegawa T, Kon S, Uede T, Matsumoto T, Saito Y, Mori S. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 2000, 20:624-628.
10. Liaw L, Lombardi DM, Almeida MM, Schwartz SM, deBlois D, Giachelli CM. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol 1997, 17:188-193.
11. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E, Geroldi D. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006, 27:802-807. 10.1093/eurheartj/ehi730, 16421174.
12. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, Ohsuzu F. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003, 170:333-337. 10.1016/S0021-9150(03)00298-3, 14612215.
13. Nilsson-Berglund LM, Zetterqvist AV, Nilsson-Ohman J, Sigvardsson M, Gonzalez Bosc LV, Smith ML, Salehi A, Agardh E, Fredrikson GN, Agardh CD, Nilsson J, Wamhoff BR, Hultgardh-Nilsson A, Gomez MF. Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia. Arterioscler Thromb Vasc Biol 2010, 30:218-224. 10.1161/ATVBAHA.109.199299, 19965778.
14. Takemoto M, Yokote K, Yamazaki M, Ridall AL, Butler WT, Matsumoto T, Tamura K, Saito Y, Mori S. Enhanced expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun 1999, 258:722-726. 10.1006/bbrc.1999.0701, 10329452.
15. Kawamura H, Yokote K, Asaumi S, Kobayashi K, Fujimoto M, Maezawa Y, Saito Y, Mori S. High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2004, 24:276-281. 10.1161/01.ATV.0000112012.33770.2a, 14670931.
16. Nicholas SB, Liu J, Kim J, Ren Y, Collins AR, Nguyen L, Hsueh WA. Critical role for osteopontin in diabetic nephropathy. Kidney Int 2010, 77:588-600. 10.1038/ki.2009.518, 20130530.
17. Endlich N, Sunohara M, Nietfeld W, Wolski EW, Schiwek D, Kranzlin B, Gretz N, Kriz W, Eickhoff H, Endlich K. Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress. FASEB J 2002, 16:1850-1852.
18. Lorenzen J, Shah R, Biser A, Staicu SA, Niranjan T, Garcia AM, Gruenwald A, Thomas DB, Shatat IF, Supe K, Woroniecki RP, Susztak K. The role of osteopontin in the development of albuminuria. J Am Soc Nephrol 2008, 19:884-890. 10.1681/ASN.2007040486, 2386721, 18443355.
19. Susztak K, Bottinger E, Novetsky A, Liang D, Zhu Y, Ciccone E, Wu D, Dunn S, McCue P, Sharma K. Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 2004, 53:784-794. 10.2337/diabetes.53.3.784, 14988265.
20. Hsieh TJ, Chen R, Zhang SL, Liu F, Brezniceanu ML, Whiteside CI, Fantus IG, Ingelfinger JR, Hamet P, Chan JS. Upregulation of osteopontin gene expression in diabetic rat proximal tubular cells revealed by microarray profiling. Kidney Int 2006, 69:1005-1015. 10.1038/sj.ki.5000206, 16528250.
21. Yamamoto N, Sakai F, Kon S, Morimoto J, Kimura C, Yamazaki H, Okazaki I, Seki N, Fujii T, Uede T. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 2003, 112:181-188. 164290, 12865407.
22. Nishimichi N, Higashikawa F, Kinoh HH, Tateishi Y, Matsuda H, Yokosaki Y. Polymeric osteopontin employs integrin alpha9beta1 as a receptor and attracts neutrophils by presenting a de novo binding site. J Biol Chem 2009, 284:14769-14776. 10.1074/jbc.M901515200, 2685658, 19346516.
23. Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007, 92:4352-4358. 10.1210/jc.2007-0933, 17785358.
24. Jax TW, Peters AJ, Plehn G, Schoebel FC. Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes - a two year follow-up of 243 patients. Cardiovasc Diabetol 2009, 8:48. 10.1186/1475-2840-8-48, 2743654, 19735543.
25. Jax TW, Peters AJ, Plehn G, Schoebel FC. Relevance of hemostatic risk factors on coronary morphology in patients with diabetes mellitus type 2. Cardiovasc Diabetol 2009, 8:24. 10.1186/1475-2840-8-24, 2688504, 19419582.
26. Kase S, Yokoi M, Saito W, Furudate N, Ohgami K, Kitamura M, Kitaichi N, Yoshida K, Kase M, Ohno S, Uede T. Increased osteopontin levels in the vitreous of patients with diabetic retinopathy. Ophthalmic Res 2007, 39:143-147. 10.1159/000102936, 17505146.
27. Hasegawa M, Nakoshi Y, Iino T, Sudo A, Segawa T, Maeda M, Yoshida T, Uchida A. Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis. J Rheumatol 2009, 36:240-245. 10.3899/jrheum.080753, 19208558.
28. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 2001, 60:1645-1657. 10.1046/j.1523-1755.2001.00032.x, 11703581.
29. Ren X, Shao H, Wei Q, Sun Z, Liu N. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res 2009, 37:847-854.
30. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009, 76:32-43. 10.1038/ki.2009.90, 19357716.
31. Fischer JW, Tschope C, Reinecke A, Giachelli CM, Unger T. Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin. Diabetes 1998, 47:1512-1518. 10.2337/diabetes.47.9.1512, 9726243.
32. Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 1998, 273:30427-30434. 10.1074/jbc.273.46.30427, 9804809.
33. Junaid A, Amara FM. Osteopontin: correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells. Histopathology 2004, 44:136-146. 10.1111/j.1365-2559.2004.01771.x, 14764057.
34. Yamaguchi H, Igarashi M, Hirata A, Tsuchiya H, Sugiyama K, Morita Y, Jimbu Y, Ohnuma H, Daimon M, Tominaga M, Kato T. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J 2004, 51:499-504. 10.1507/endocrj.51.499, 15516785.
35. Shio K, Kobayashi H, Asano T, Saito R, Iwadate H, Watanabe H, Sakuma H, Segawa T, Maeda M, Ohira H. Thrombin-cleaved osteopontin is increased in urine of patients with rheumatoid arthritis. J Rheumatol 2010, 37:704-710. 10.3899/jrheum.090582, 20156944.
36. Lai CF, Seshadri V, Huang K, Shao JS, Cai J, Vattikuti R, Schumacher A, Loewy AP, Denhardt DT, Rittling SR, Towler DA. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 2006, 98:1479-1489. 10.1161/01.RES.0000227550.00426.60, 16709900.
37. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581. 10.1001/jama.287.19.2570, 12020339.